Co-Diagnostics shares soar as its technology is used in Stanford cancer study

The aim of the Stanford study is to find better ways to detect genetic mutations which surface in lung cancer

Cancer headline in a newspaper
Co-Diagnostics shares are up sharply in pre-market trade

Investors sent shares in Co-Diagnostics Inc. (NASDAQ: CODX) flying in pre-market trade on the news that its CoPrimer technology will be used in a Stanford University research project.

The point of the study, which is being conducted by the Wang Group at Stanford, is to find better ways to detect genetic mutations in the epidermal growth factor receptor gene that surface in lung cancer.

Co-Diagnostics’ CoPrimer technology is being used by the scientists at Stanford to improve their detection methods of the mutations which cause cancer. The results of the Stanford study will be published later this year.

In response to the news, Co-Diagnostics shares jumped 12.4% to US$2.90 in pre-market trade.

“Heightened specificity and allowing for a massive reduction in false positives, are [two] of the most valuable benefits of this technology, making it ideal for cancer detection and liquid biopsy applications,” Dwight Egan, chief executive of Co-Diagnostics, said.

Based in Utah, Co-Diagnostics is a company which develops diagnostic equipment used to detect and analyze DNA and RNA.


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Shield Therapeutics to present data showing Feraccru offers 'real oral...

Shield Therapeutics PLC's (LON:STX) Dr Mark Sampson speaks to Proactive London's Andrew Scott ahead of them presenting positive data from the Phase 3b, open-label randomised controlled trial of Feraccru. He says the trial shows the drug, also known as Accrufer in the States, offers a real...

14 hours, 50 minutes ago

2 min read